Sebela Women's Health

Sebela Women's Health is the specialized division of Sebela Pharmaceuticals dedicated to improving the lives of women through innovative therapeutic solutions. The company maintains a strong commercial presence in the United States, featuring a portfolio of products that address contraception, menopause-related vasomotor symptoms, and vulvar and vaginal atrophy. Key products include ANNOVERA, IMVEXXY, and BIJUVA, which were added to the portfolio through the strategic acquisition of TherapeuticsMD's assets in 2022. Beyond its commercial offerings, Sebela is actively developing Veracept, a next-generation, low-dose copper intrauterine device currently in Phase 3 clinical trials. The company leverages a combination of internal development and strategic business development to expand its leadership in the women's health sector.